A review of 11 observational studies (8 of which were conducted in China), led them to conclude “that there is low-certainty evidence that patients on long-term therapy with ACE inhibitors or ARBs are not at risk of poor outcomes from COVID-19”. Furthermore, from the results of their recent observational study in Medicare and commercially insured populations, Khera et al. conclude that “the use of ACE inhibitors and ARBs was not associated with the risk of hospitalization or mortality among those infected with SARS-CoV-2” [17]. Here, ACE is linked to COVID-19.